Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Novel vaccine candidates for an improved a cellular vaccine of B. pertussis
International Conference & Exhibition on Vaccines & Vaccination
22-24 Nov 2011 Philadelphia Airport Marriott, USA

Mar�a Eugenia Rodriguez

Scientific Tracks Abstracts: J Vaccines Vaccin


Bordetella pertussis is the etiologic agent of whooping cough. Despite the high coverage of vaccination the disease is still a major public health problem worldwide which is a refl ect of the low effi ciency of current vaccines. Th e diff erence between the phenotype of the infecting bacteria and the vaccine phenotype seems to contribute to this lack of protection. Antigenic proteins whose expression is induced under iron starvation, an environmental condition that bacterial pathogens have to face during colonization, might be potential candidates for improved vaccines. By mean of immune proteomics we identifi ed novel antigens of B. pertussis maximally expressed under iron starvation. Among the proteins diff erentially recognized by human sera from infected individuals, two proteins showed highly protective in cellular formulations against pertussis infection, namely AfuA (Bp1605) and IRP1-3 (Bp1152). IRP1- 3 and AfuA were identifi ed as putative iron binding proteins using matrix-assisted laser desorption ionization�time of fl ight (MALDITOF/TOF) mass spectrometry. In this study, we cloned, expressed and purifi ed the two recombinant proteins from Escherichia coli. Th e protective activity of these antigens was evaluated in BALB/c mice using the intranasal infection model. Our results demonstrated that although vaccination with either AfuA or IRP1- 3 signifi cantly (p<0.01) protected the mice against intranasal infection of B. pertussis , AfuA vaccination rendered a higher level of protection. Th e divalent formulation reduced bacterial burden to a degree that suggests a synergistic eff ect of both antigens. Analysis of antibody biological activity in protected mice revealed that both AfuA and IRP1-3 led to the generation of specifi c antibodies able to recognize the respective native proteins on bacterial surface and to induce effi cient bacterial phagocytosis, one of the main antibody protective activities against this pathogen. Analysis of cytokines in protected mice revealed the induction of a balanced Th 1/Th 2 type of response by IRP1-3. AfuA, however, promoted an immune response with a remarkable cellular immunity contribution which might explain the higher protection induced by this protein. Given the recent discovery that B. pertussis has an intracellular phase that might represent the niche of persistence, this kind of antigens are particularly interesting for an eff ective vaccine formulation. Immunoblot analysis demonstrated that the two proteins are expressed by clinical isolates under iron starvation. Th is observation, together with the presence of antibodies against these proteins in sera from infected individuals, confi rmed their expression during human pertussis infection. Altogether our results point at these two antigens as promising new candidates to improve current pertussis vaccines

Biography :

Prof. Rodriguez completed her Ph.D at the National University of La Plata (Argentina) and postdoctoral studies at the Laboratory for Vaccine Research Development and Research on Immune mechanisms (LVM). National Institute of Public Health and the Environment (RIVM). (Netherlands), and Laboratory of Immune Therapy and Experimental Immunology. Department of Immunology, Utrecht University (the Netherlands). She is presently a Professor at the National University of La Plata and Scienti fi c Researcher of the National Research Council at the Applied Biotechnology Center (CONICET- UNLP) in Argentine. He has published more than 30 papers in reputed journals on infectious diseases and immunity, and serving as a reviewer of many repute scienti fi c journals